| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net income (loss) | ||||||
-22,722 | -39,128 | -74,865 | -94,176 | -27,255 | -17,917 | -16,197 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||
Amortization expense | ||||||
14,752 | 109,834 | - | 397 | - | - | - |
Depreciation expense | ||||||
731 | 1,074 | 594 | 655 | 171 | 187 | - |
Non-cash impairment charges | ||||||
- | - | 1,845 | - | - | - | - |
Depreciation expense | ||||||
- | - | - | - | - | - | 169 |
Lease incentive obligation | ||||||
- | - | 34 | 34 | 34 | 34 | 34 |
Stock-based compensation expense | ||||||
16,528 | 13,778 | 7,945 | 5,787 | 2,209 | 22 | 62 |
Non-cash lease expense | ||||||
313 | - | - | - | - | - | - |
Non-cash interest expense for Nucynta asset acquisition | ||||||
- | 19,281 | - | - | 6 | 7 | 12 |
Change in fair value of derivative liability | ||||||
- | - | - | - | - | -7 | -79 |
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
-4,993 | 68,231 | 7,840 | 2,129 | - | - | - |
Inventory | ||||||
1,826 | -219 | 497 | 1,316 | - | - | - |
Prepaid expenses and other assets | ||||||
-2,037 | 166 | 1,057 | 923 | 659 | -183 | 11 |
Refundable PDUFA fee | ||||||
- | - | - | - | -2,335 | 2,335 | - |
Accounts payable | ||||||
-5,903 | 6,465 | -3,422 | 5,569 | 1,298 | 990 | -822 |
Accrued expenses | ||||||
6,056 | 18,995 | -527 | 6,570 | 362 | 943 | 199 |
Accrued rebates, returns and discounts | ||||||
12,766 | 106,593 | 15,784 | - | - | - | - |
Operating lease assets and liabilities | ||||||
734 | - | - | - | - | - | - |
Deferred revenue | ||||||
- | - | -4,944 | 4,944 | - | - | - |
Other long-term liabilities | ||||||
-676 | 676 | - | - | - | - | - |
Net cash used in operating activities | ||||||
27,783 | 169,390 | -67,018 | -75,053 | -21,567 | -17,947 | -16,530 |
Investing activities | ||||||
Purchase of intangible asset | ||||||
- | 18,877 | - | 2,500 | - | - | - |
Purchases of property and equipment | ||||||
6,438 | 5,477 | 990 | 477 | 362 | 8 | 206 |
Net cash used in investing activities | ||||||
-6,438 | -24,354 | -990 | -2,977 | -362 | -8 | -206 |
Financing activities | ||||||
Issuance costs from issuance of common stock | ||||||
- | - | - | 845 | - | - | - |
Proceeds from issuances of common stock from employee stock purchase plans | ||||||
817 | 1,117 | 1,141 | 442 | - | - | - |
Repayment of lease note payable | ||||||
- | - | - | - | 59 | 62 | 62 |
Restricted cash | ||||||
- | - | - | - | -16 | - | - |
Repayment of term note | ||||||
- | - | - | - | - | 28 | 43 |
Proceeds from the exercise of stock options | ||||||
2,046 | 4,255 | 736 | 443 | 517 | 72 | 1 |
Payments made for employee restricted stock tax withholdings | ||||||
822 | 560 | 68 | - | - | - | - |
Net (decrease) increase in cash and cash equivalents | ||||||
- | - | - | - | 94,063 | - | - |
Proceeds from issuance of convertible bridge note | ||||||
- | - | - | - | - | 5,000 | - |
Proceeds from issuances of common stock from public offerings, net of issuance costs of $-, $30 and $1,198, respectively | ||||||
- | -30 | 34,338 | 137,340 | 72,029 | - | - |
Proceeds from term loan amendment, net of repayment of amended term loan | ||||||
- | 10,021 | - | - | - | - | - |
Proceeds from issuance of Series D convertible redeemable preferred stock, net of issuance costs of $193 | ||||||
- | - | - | - | 44,807 | - | - |
Repayment of term loan | ||||||
- | - | 2,667 | 2,667 | 1,286 | - | - |
Proceeds from term loan amendment, net of repayment of amended term loan | ||||||
- | - | - | - | - | 7,056 | 500 |
Repayment of asset acquisition obligations | ||||||
- | 132,000 | - | - | - | - | - |
Net cash provided by financing activities | ||||||
2,041 | -117,197 | 33,480 | 135,558 | 115,992 | 12,038 | 12,351 |
Net decrease in cash, cash equivalents and restricted cash | ||||||
23,386 | 27,839 | -34,528 | 57,528 | - | -5,917 | -4,385 |
Supplemental disclosure of cash flow information | ||||||
Cash paid for offering costs | ||||||
- | 30 | 1,228 | - | - | - | - |
Cash paid for interest | ||||||
709 | 582 | 139 | 284 | 353 | 181 | 73 |
Supplemental disclosure of non-cash activities | ||||||
Acquisition of property and equipment in accounts payable and accrued expenses | ||||||
134 | 3,261 | 216 | 81 | - | - | - |
Term notes issuance costs in accounts payable and accrued expenses | ||||||
- | - | - | - | - | - | 13 |
Operating lease assets assumed | ||||||
9,957 | - | - | - | - | - | - |
Operating lease liabilities assumed | ||||||
10,691 | - | - | - | - | - | - |
Liabilities assumed from Nucynta asset acquisition included in accrued rebates, returns and discounts | ||||||
- | 22,406 | - | - | - | - | - |
Liabilities assumed from Nucynta asset acquisition included as a reduction to accounts receivable | ||||||
- | 254 | - | - | - | - | - |
Warrant issued in connection with Nucynta asset acquisition | ||||||
- | 8,043 | - | - | - | - | - |
Preferred stock conversion to common stock | ||||||
- | - | - | - | 120,302 | - | - |
Extinguishment of preferred stock | ||||||
- | - | - | - | 31,184 | - | - |
Accruals of dividends and accretion to redemption value | ||||||
- | - | - | - | 24,572 | 3,300 | - |
Conversion of bridge note to preferred stock | ||||||
- | - | - | - | 5,000 | - | 2,926 |
Repayment of term note with proceeds of notes payable | ||||||
- | - | - | - | - | 944 | - |
Performance Adjustment to Series A and common shares | ||||||
- | - | - | - | - | - | 12,239 |